Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carbetocin - Ferring Pharmaceuticals

Drug Profile

Carbetocin - Ferring Pharmaceuticals

Alternative Names: Carbetocin Ferring; CARITEC; Duratobal; Duratocin; Lonactene; Pabal

Latest Information Update: 06 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Ferring Pharmaceuticals; Merck & Co; Sun Pharmaceutical Industries; World Health Organization
  • Class Antihaemorrhagics; Oxytocics; Posterior pituitary hormones
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Postpartum haemorrhage; Uterine inertia

Most Recent Events

  • 21 Sep 2023 Ferring Pharmaceuticals completes a phase I trial in Postpartum haemorrhage (In volunteers) in USA (IV) (NCT05924321)
  • 25 May 2023 Phase-I clinical trials in Postpartum haemorrhage (In adults, In volunteers) in USA (IV, Infusion) (NCT05924321)
  • 28 Apr 2023 Phase-III clinical trials in Postpartum haemorrhage in USA (IV) prior to April 2023 (Ferring Pharmaceuticals pipeline, April 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top